A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Terlipressin (Primary)
  • Indications Hepatorenal syndrome
  • Focus Therapeutic Use
  • Sponsors Orphan Therapeutics
  • Most Recent Events

    • 24 Oct 2017 Results (n=308) assessing changes in C-S scores and ACLF grades using patient data pooled from REVERSE and OT-0401 trials presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 24 Oct 2017 Results (n=125) of pooled analysis of OT-0401 and REVERSE trials using patients recruited from US sites assessing efficacy of terlipressin vs placebo presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 29 Mar 2017 Results of pooled anlaysis of two phase III studies (REVERSE and OT-0401) published in the Alimentary Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top